Please login to the form below

Not currently logged in
Email:
Password:

AZ settles Seroquel patent case

AstraZeneca has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR in the US

AstraZeneca (AZ) has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR (quetiapine humarate) in the US.

AZ filed litigation against Accord following the company's submission to the US Food and Drug Administration (FDA) of an abbreviated new drug application for a generic version of the depression treatment.

As part of the agreement, AZ has granted Accord a licence to enter the US market with its generic Seroquel XR on November 1, 2016, or earlier, depending upon certain circumstances.

The drug is protected by patents and other exclusivity rights that range from March 2012 to November 2017.

Remaining Seroquel XR patent infringement litigations are ongoing.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics